VKTX - NASDAQ
Viking Therapeutics, Inc.
$29.33
+0.037%Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotViking Therapeutics, Inc. Management Team
Dr. Geoffrey E. Barker Ph.D.
Chief Development Officer
Mr. Gregory S. Zante CPA, CPA
Chief Financial Officer
Compensation
$713,000
Ms. Marianne Mancini
Chief Operating Officer
Compensation
$735,000
Dr. Brian Lian Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,193,748
Mr. Michael Morneau
Vice President of Finance & Administration
Compensation
$375,333
Viking Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $150K and sold $5.95M worth of VKTX shares, resulting in $5.80M of net selling activity.
3 Months
4.5K
149.91K
0
0.00
+150K
+$150K
3-6 Months
0
0.00
32.0K
1.03M
-1.0M
-$1.03M
6-9 Months
0
0.00
111.4K
3.93M
-3.9M
-$3.93M
9-12 Months
0
0.00
35.4K
984.53K
-985K
-$985K
Top Buyers
Aubuchon Neil William
Officer: Chief Commercial Officer
$150K
Top Sellers
Rowland Charles A Jr
Director
$2.13M
Lian Brian
Director, Officer: President & Ceo
$2.11M
Zante Greg
Officer: Chief Financial Officer
$1.37M
Mancini Marianna
Officer: Chief Operating Officer
$335K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5.80M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
VKTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 19, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2025 | May 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 21, 2024 | 2024 | |
DEF 14A DEF 14A N/A | May 01, 2023 | May 01, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 08, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 06, 2020 | May 21, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 05, 2019 | May 23, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 06, 2018 | May 24, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 07, 2017 | May 23, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.